325 related articles for article (PubMed ID: 32427375)
1. Antitumor efficacy of interferon-γ-modified exosomal vaccine in prostate cancer.
Shi X; Sun J; Li H; Lin H; Xie W; Li J; Tan W
Prostate; 2020 Aug; 80(11):811-823. PubMed ID: 32427375
[TBL] [Abstract][Full Text] [Related]
2. PD-1 blockade enhances the antitumor efficacy of GM-CSF surface-modified bladder cancer stem cells vaccine.
Shi X; Zhang X; Li J; Mo L; Zhao H; Zhu Y; Hu Z; Gao J; Tan W
Int J Cancer; 2018 May; 142(10):2106-2117. PubMed ID: 29243219
[TBL] [Abstract][Full Text] [Related]
3. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
4. Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy.
Rountree RB; Mandl SJ; Nachtwey JM; Dalpozzo K; Do L; Lombardo JR; Schoonmaker PL; Brinkmann K; Dirmeier U; Laus R; Delcayre A
Cancer Res; 2011 Aug; 71(15):5235-44. PubMed ID: 21670078
[TBL] [Abstract][Full Text] [Related]
5. Depletion of regulatory T cells by anti-ICOS antibody enhances anti-tumor immunity of tumor cell vaccine in prostate cancer.
Mo L; Chen Q; Zhang X; Shi X; Wei L; Zheng D; Li H; Gao J; Li J; Hu Z
Vaccine; 2017 Oct; 35(43):5932-5938. PubMed ID: 28923424
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer.
Cappuccini F; Stribbling S; Pollock E; Hill AV; Redchenko I
Cancer Immunol Immunother; 2016 Jun; 65(6):701-13. PubMed ID: 27052571
[TBL] [Abstract][Full Text] [Related]
7. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470
[TBL] [Abstract][Full Text] [Related]
8. PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer.
Shi X; Zhang X; Li J; Zhao H; Mo L; Shi X; Hu Z; Gao J; Tan W
Cancer Lett; 2017 Oct; 406():27-35. PubMed ID: 28797844
[TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity.
Xie Y; Bai O; Zhang H; Li W; Xiang J
Cancer Biother Radiopharm; 2010 Feb; 25(1):21-8. PubMed ID: 20187793
[TBL] [Abstract][Full Text] [Related]
10. Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer.
Hannan R; Zhang H; Wallecha A; Singh R; Liu L; Cohen P; Alfieri A; Rothman J; Guha C
Cancer Immunol Immunother; 2012 Dec; 61(12):2227-38. PubMed ID: 22644735
[TBL] [Abstract][Full Text] [Related]
11. Harnessing T-cell activity against prostate cancer: A therapeutic microparticulate oral cancer vaccine.
Parenky AC; Akalkotkar A; Mulla NS; D'Souza MJ
Vaccine; 2019 Sep; 37(41):6085-6092. PubMed ID: 31477437
[TBL] [Abstract][Full Text] [Related]
12. Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model.
Simons BW; Cannella F; Rowley DT; Viscidi RP
Cancer Immunol Immunother; 2020 Apr; 69(4):641-651. PubMed ID: 32016503
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models.
Lu Z; Zuo B; Jing R; Gao X; Rao Q; Liu Z; Qi H; Guo H; Yin H
J Hepatol; 2017 Oct; 67(4):739-748. PubMed ID: 28549917
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of Anti-Leukemia Immunity by Leukemia-Derived Exosomes Via Downregulation of TGF-β1 Expression.
Huang F; Wan J; Hu W; Hao S
Cell Physiol Biochem; 2017; 44(1):240-254. PubMed ID: 29130994
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy.
Winter H; Hu HM; McClain K; Urba WJ; Fox BA
J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488
[TBL] [Abstract][Full Text] [Related]
16. HCA587 Protein Vaccine Induces Specific Antitumor Immunity Mediated by CD4
Yang W; Zhang W; Wang X; Tan L; Li H; Wu J; Wu Q; Sun W; Chen J; Yin Y
Anticancer Agents Med Chem; 2021; 21(6):738-746. PubMed ID: 32723258
[TBL] [Abstract][Full Text] [Related]
17. Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway.
Li X; Wang S; Mu W; Barry J; Han A; Carpenter RL; Jiang BH; Peiper SC; Mahoney MG; Aplin AE; Ren H; He J
J Exp Clin Cancer Res; 2022 Jan; 41(1):41. PubMed ID: 35086548
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model.
Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
Immunol Lett; 2007 Nov; 113(2):90-8. PubMed ID: 17913245
[TBL] [Abstract][Full Text] [Related]
19. Surface anchorage of superantigen SEA promotes induction of specific antitumor immune response by tumor-derived exosomes.
Xiu F; Cai Z; Yang Y; Wang X; Wang J; Cao X
J Mol Med (Berl); 2007 May; 85(5):511-21. PubMed ID: 17219095
[TBL] [Abstract][Full Text] [Related]
20. Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response.
Zhao L; Mei Y; Sun Q; Guo L; Wu Y; Yu X; Hu B; Liu X; Liu H
J Immunol; 2014 Jul; 193(2):735-45. PubMed ID: 24943214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
